• cerbomed

  Led · Equity · Sep 2012

  Cerbomed, founded in 2005 and based in Erlangen, Germany, focuses on neuromodulation using transcutaneous vagus nerve stimulation (t-VNS). Its lead product, the NEMOS t-VNS device, received CE clearance for epilepsies and depression in 2010 and for pain in 2012 and is available in Germany and Austria. The company is currently running clinical studies on t-VNS for drug-resistant epilepsy and chronic migraine. Cerbomed's investor base includes lead investor MIG AG, as well as KfW Banking Group and S-Refit AG. The company announced a strategic, minority investment from Cyberonics that will primarily fund its ongoing epilepsy clinical trial in Germany. Cyberonics also holds certain shareholder rights, including advisory-board representation and an exclusive option for worldwide sales and distribution of NEMOS, and may conduct a U.S. trial aimed at FDA approval subject to conditions.

• ImThera Medical

  Led · Equity · Oct 2011

  ImThera Medical develops a novel implantable neurostimulation device that delivers muscle tone to key tongue muscles during sleep to open the upper airway and reduce or eliminate obstructive sleep apnea events. The company is led by Chairman, President and CEO Marcelo Lima. ImThera is pursuing CE Mark regulatory approval in the European Union and expects to initiate a pivotal clinical trial in the U.S. in the near future. Financially, the company is executing a Series C that includes an initial $4M investment from Cyberonics and the potential to expand that investment to $12M upon achievement of regulatory and clinical milestones. Cyberonics will be a minority shareholder and take a board seat. ImThera also plans to raise up to $4M from private investors, bringing the Series C to up to $16M.

• NeuroVista

  Participated · Convertible Note · Aug 2010

  NeuroVista is developing a Seizure Advisory System — an implantable device that senses irregularities in brain electrical waves that precede a seizure. The device is designed to give early warnings so patients can take medicine or find a safe place to lie down. The company is advancing the technology through clinical trials, and the recent financing is intended to support those ongoing trials. NeuroVista closed $16.5M in equity financing and also secured a $5M convertible debt agreement. As part of the financing, Dr. Steve Gourlay of GBS joined NeuroVista's board. The funding will be used to further clinical development of the platform. NeuroVista develops implantable devices aimed at treating epilepsy. The company, founded in 2002 by Daniel DiLorenzo and based in Seattle, has been publicly quiet about its technology and commercial direction. In April, DiLorenzo received a patent for a "neurological control system" using "closed-loop intracranial stimulation" for the optimal control of neurological disease, suggesting systems that monitor and potentially counteract early signs of seizures. The company completed a $33.8 million second-round funding, which should support further development of its technology. NeuroVista previously operated under the name BioNeuronics. Other firms, including NeuroPace, Medtronic, and Cyberonics, are also reported to be researching epilepsy devices, indicating a competitive landscape.

No current team members are available.